Sean A Dilliard
Overview
Explore the profile of Sean A Dilliard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
954
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vaidya A, Moore S, Chatterjee S, Guerrero E, Kim M, Farbiak L, et al.
Adv Mater
. 2024 Jul;
36(35):e2313791.
PMID: 38973655
Inhibition of disease-causing mutations using RNA interference (RNAi) has resulted in clinically approved medicines with additional candidates in late stage trials. However, targetable tissues currently in preclinical development are limited...
2.
Sun Y, Chatterjee S, Lian X, Traylor Z, Sattiraju S, Xiao Y, et al.
Science
. 2024 Jun;
384(6701):1196-1202.
PMID: 38870301
In vivo genome correction holds promise for generating durable disease cures; yet, effective stem cell editing remains challenging. In this work, we demonstrate that optimized lung-targeting lipid nanoparticles (LNPs) enable...
3.
Lian X, Chatterjee S, Sun Y, Dilliard S, Moore S, Xiao Y, et al.
Nat Nanotechnol
. 2024 May;
19(9):1409-1417.
PMID: 38783058
Therapeutic genome editing of haematopoietic stem cells (HSCs) would provide long-lasting treatments for multiple diseases. However, the in vivo delivery of genetic medicines to HSCs remains challenging, especially in diseased...
4.
Dilliard S, Sun Y, Brown M, Sung Y, Chatterjee S, Farbiak L, et al.
J Control Release
. 2023 Aug;
361:361-372.
PMID: 37536547
Messenger RNA (mRNA) can treat genetic disease using protein replacement or genome editing approaches but requires a suitable carrier to circumnavigate biological barriers and access the desired cell type within...
5.
Dilliard S, Siegwart D
Nat Rev Mater
. 2023 Jan;
8(4):282-300.
PMID: 36691401
Genetic drugs based on nucleic acid biomolecules are a rapidly emerging class of medicines that directly reprogramme the central dogma of biology to prevent and treat disease. However, multiple biological...
6.
Johnson L, Zhang D, Zhou K, Lee S, Liu S, Dilliard S, et al.
Mol Pharm
. 2022 Sep;
19(11):3973-3986.
PMID: 36154076
Within the field of lipid nanoparticles (LNPs) for RNA delivery, the focus has been mainly placed on organ level delivery, which can mask cellular level effects consequential to therapeutic applications....
7.
Dilliard S, Siegwart D
Nat Biomed Eng
. 2022 Feb;
6(2):106-107.
PMID: 35190677
No abstract available.
8.
Dilliard S, Cheng Q, Siegwart D
Proc Natl Acad Sci U S A
. 2021 Dec;
118(52).
PMID: 34933999
Lipid nanoparticles (LNPs) are a clinically mature technology for the delivery of genetic medicines but have limited therapeutic applications due to liver accumulation. Recently, our laboratory developed selective organ targeting...
9.
Cheng Q, Wei T, Farbiak L, Johnson L, Dilliard S, Siegwart D
Nat Nanotechnol
. 2020 Apr;
15(4):313-320.
PMID: 32251383
CRISPR-Cas gene editing and messenger RNA-based protein replacement therapy hold tremendous potential to effectively treat disease-causing mutations with diverse cellular origin. However, it is currently impossible to rationally design nanoparticles...
10.
Lapin N, Vergara L, Mackeyev Y, Newton J, Dilliard S, Wilson L, et al.
Int J Nanomedicine
. 2017 Nov;
12:8289-8307.
PMID: 29180866
[60]Fullerene is a highly versatile nanoparticle (NP) platform for drug delivery to sites of pathology owing to its small size and both ease and versatility of chemical functionalization, facilitating multisite...